Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEPLISAV-B vs Engerix-B in Adults with CKD
NCT00985426Phase 3Completed
- Sponsor
- Dynavax Technologies
- Start
- Sep 2009
- Primary completion
- Jan 2012
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of Heplisav-B in hepatitis B (HBV) (2 arms), sponsored by Dynavax Technologies. Primary endpoint: Seroprotection Rate at Week 28. Started Sep 2009; status: completed.
02
Drugs
Heplisav-B
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT00985426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00985426.